Document Detail


Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers.
MedLine Citation:
PMID:  12404884     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The purpose of these studies was to evaluate the effect of lerisetron (1-phenyl-methyl-2-piperazinyl-1H-benzimidazole hydrochloride, CAS 143257-98-1, F-0930-RS2), a new 5-HT3 receptor antagonist, on ipecacuanha-induced nausea and vomiting. The ipecacuanha model of emesis has been used to test the anti-emetic activity of several different 5-HT3 antagonists and the anti-emetic doses that were effective in the ipecacuanha model have been found to correlate well with the clinically effective doses. Study 1 investigated oral doses of lerisetron from 4 mg to 40 mg. Study 2 evaluated the duration of effect of a single dose of 20 mg oral lerisetron. Study 3 evaluated intravenous doses of 18 mg and 12 mg lerisetron. In Study 1, the 40 mg dose of oral lerisetron inhibited emesis in all test subjects. The percentage of subjects who experienced an emetic episode increased as the dose of lerisetron decreased. At the lowest dose level tested five of six subjects had an emetic episode compared with four out of five in the placebo group. In Study 2, 20 mg oral lerisetron was effective up to 12 h after administration. When ipecacuanha was administered at 18 h post-dose three of seven subjects had an emetic episode and at 24 h post-dose the incidence of emesis was similar to the placebo treatment groups in the previous study. Study 3 demonstrated the effectiveness of intravenous doses of lerisetron. The 18 mg intravenous dose reduced the number of patients experiencing emetic episodes by 75% compared with placebo, doses below 12 mg i.v. were not evaluated because of the reduced efficacy of the compound at this dose level. In conclusion, lerisetron has been shown to be effective in the treatment of ipecacuanha-induced nausea and vomiting at intravenous doses of 18 mg and at oral doses of 20 mg for up to 12 hours.
Authors:
Mark Cooper; Ander Sologuren; Roman Valiente; Jeffery Smith
Related Documents :
2169784 - Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexameth...
8674154 - A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetr...
7513844 - Clinical efficacy of recombinant human granulocyte colony-stimulating factor in patient...
3780824 - Antiemetic effect and pharmacokinetics of high dose metoclopramide in cancer patients t...
19539004 - A study to estimate and correlate cigarette smoke exposure in smokers in germany as det...
3842184 - Prophylactic and antidotal effects of hexamethylenetetramine against phosgene poisoning...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Arzneimittel-Forschung     Volume:  52     ISSN:  0004-4172     ISO Abbreviation:  Arzneimittelforschung     Publication Date:  2002  
Date Detail:
Created Date:  2002-10-30     Completed Date:  2002-11-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0372660     Medline TA:  Arzneimittelforschung     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  689-94     Citation Subset:  IM    
Affiliation:
Simbec Research Ltd., Merthyr Tydfil, UK. mark.cooper@simbec.co.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adolescent
Adult
Antiemetics / administration & dosage,  pharmacology*
Benzimidazoles / administration & dosage,  pharmacology*
Dose-Response Relationship, Drug
Emetics*
Granisetron / pharmacology
Humans
Injections, Intravenous
Ipecac*
Male
Nausea / chemically induced,  prevention & control
Piperidines / administration & dosage,  pharmacology*
Receptors, Serotonin / drug effects*
Receptors, Serotonin, 5-HT3
Serotonin Antagonists / administration & dosage,  pharmacology*
Time Factors
Vomiting / chemically induced,  prevention & control*
Chemical
Reg. No./Substance:
0/Antiemetics; 0/Benzimidazoles; 0/Emetics; 0/Piperidines; 0/Receptors, Serotonin; 0/Receptors, Serotonin, 5-HT3; 0/Serotonin Antagonists; 109889-09-0/Granisetron; 143257-98-1/lerisetron; 8012-96-2/Ipecac

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Improvement of the bioavailability of colchicine in rats by co-administration of D-alpha-tocopherol ...
Next Document:  Total synthesis and anti-leishmanial activity of some curcumin analogues.